Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Leuk Res. 2018 Aug 6;72:59–66. doi: 10.1016/j.leukres.2018.08.002

Fig. 5.

Fig. 5.

Anti-leukemic activity of the combination therapy of cabazitaxel and plicamycin in co-culture. REH (A & B) and SUPB15 (C & D) were grown in a co-culture with osteoblast (HOB) in a 24 well plate for 12 days. On day 10 in co-culture, the cells were treated with either 3 nM of cabazitaxel (CAB) or 15 nM of Plicamycin (PLI) or their combination (C + P). All drugs were delivered in a nanoparticle encapsulated formulation. At the end of treatment, the live cells were counted, using trypan blue dye exclusion method, in suspension (S) and phase dim (PD) population when in co-culture using REH (A) and SUPB15 (C). The total cells and the live cell population was used to calculate the % viability in REH (B) and SUPB15 (D). The data is presented as Mean ± SEM and is a representative of a study performed in triplicate and conducted three independent times. *P < 0.05, when compared to all treatment groups.